1. Headline
  1. Headline
By
updated 9/22/2011 12:32:55 PM ET 2011-09-22T16:32:55

Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government's latest attempt to protect the Earth's atmosphere.

  1. More from TODAY.com
    1. Buying running shoes? Here’s what to expect

      Whether you are thinking about signing up for your first 5K or are gearing up for a full marathon, the first two steps in ...

    2. 'Sex Box': Couples therapy or reality show trash?
    3. Food-themed hotels are popping up around the world
    4. Catch up on all the news of the week with ‘The Download’
    5. Missing Oscar dress worn by Lupita Nyong’o may be found

The Food and Drug Administration said Thursday patients who use the epinephrine inhalers to treat mild asthma will need to switch by Dec. 31 to other types that do not contain chlorofluorocarbons, an aerosol substance once found in a variety of spray products.

The action is part of an agreement signed by the U.S. and other nations to stop using substances that deplete the ozone layer, a region in the atmosphere that helps block harmful ultraviolet rays from the Sun.

But the switch to a greener inhaler will cost consumers more. Epinephrine inhalers are available via online retailers for around $20, whereas the alternatives, which contain the drug albuterol, range from $30 to $60.

The FDA finalized plans to phase out the products in 2008 and currently only Armstrong Pharmaceutical's Primatene mist is available in the U.S. Other manufacturers have switched to an environmentally-friendly propellant called hydrofluoroalkane. Both types of inhalers offer quick-relief to symptoms like shortness of breath and chest tightness, but the environmentally-friendly inhalers are only available via prescription.

"If you rely on an over-the-counter inhaler to relieve your asthma symptoms, it is important that you contact a health care professional to talk about switching to a different medicine to treat your asthma," said Badrul Chowdhury, FDA's director of pulmonary drug division.

Chowdhury told reporters and doctors via teleconference that "in the worst case scenario we are looking at 1 to 2 million people using" Primatene, adding that most of those patients likely use multiple medications to treat their asthma.

Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

More on TODAY.com

  1. Shutterstock

    Buying running shoes? Here’s what to expect

    2/28/2015 12:52:17 PM +00:00 2015-02-28T12:52:17
  1. TODAY

    'Sex Box': Couples therapy or reality show trash?

    2/28/2015 2:57:40 PM +00:00 2015-02-28T14:57:40
  1. Unique Vision Photography

    Since groom's moving vows to stepdaughter, this blended family's grown

    2/27/2015 10:04:41 PM +00:00 2015-02-27T22:04:41
  1. TODAY

    video Catch up on all the news of the week with ‘The Download’

    2/28/2015 12:58:44 PM +00:00 2015-02-28T12:58:44
  1. TODAY

    video Jeb Bush tries to make the case for 2016 to conservatives at CPAC

    2/28/2015 12:30:14 PM +00:00 2015-02-28T12:30:14